Publications

Stem Cells and Organoid Technology in Precision Medicine in Inflammation: Are We There Yet?

Florian Tran, Christine Klein, Alexander Arlt, Simon Imm, Evelyn Knappe, Alison Simmons, Philip Rosenstiel, Philip Seibler
Front Immunol. 2020 Dec 21;11:573562. doi: 10.3389/fimmu.2020.573562. eCollection 2020.
https://pubmed.ncbi.nlm.nih.gov/33408713/

DNA Methylation as a Potential Molecular Mechanism in X-linked Dystonia-Parkinsonism

Krause C, Schaake S, Grütz K, Sievert H, Reyes CJ, König IR, Laabs BH, Jamora RD, Rosales RL, Diesta CCE, Pozojevic J, Gemoll T, Westenberger A, Kaiser FJ, Klein C, Kirchner H
Mov Disord. 2020 Dec;35(12):2220-2229. doi: 10.1002/mds.28239. Epub 2020 Sep 10.
https://pubmed.ncbi.nlm.nih.gov/32914507/

Variants in the SK2 channel gene (KCNN2) lead to dominant neurodevelopmental movement disorders

Fanny Mochel, Agnès Rastetter, Berten Ceulemans, Konrad Platzer, Sandra Yang, Deepali N Shinde, Katherine L Helbig, Diego Lopergolo, Francesca Mari, Alessandra Renieri, Elisa Benetti, Roberto Canitano, Quinten Waisfisz, Astrid S Plomp, Sylvia A Huisman, Golder N Wilson, Sara S Cathey, Raymond J Louie, Daniela Del Gaudio, Darrel Waggoner, Shawn Kacker, Kimberly M Nugent, Elizabeth R Roeder, Ange-Line Bruel, Julien Thevenon, Nadja Ehmke, Denise Horn, Manuel Holtgrewe, Frank J Kaiser, Susanne B Kamphausen, Rami Abou Jamra, Sarah Weckhuysen, Carine Dalle, Christel Depienne
Brain. 2020 Dec 1;143(12):3564-3573. doi: 10.1093/brain/awaa346.
https://pubmed.ncbi.nlm.nih.gov/33242881/

Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism

Borsche M, König IR, Delcambre S, Petrucci S, Balck A, Brüggemann N, Zimprich A, Wasner K, Pereira SL, Avenali M, Deuschle C, Badanjak K, Ghelfi J, Gasser T, Kasten M, Rosenstiel P, Lohmann K, Brockmann K, Valente EM, Youle RJ, Grünewald A, Klein C
Brain. 2020 Oct 1;143(10):3041-3051. doi: 10.1093/brain/awaa246.
https://pubmed.ncbi.nlm.nih.gov/33029617/

Parkin-linked Parkinson’s disease: From clinical insights to pathogenic mechanisms and novel therapeutic approaches

Wasner K, Grünewald A, Klein C
Neurosci Res. 2020 Oct;159:34-39. doi: 10.1016/j.neures.2020.09.001. Epub 2020 Sep 17.
https://pubmed.ncbi.nlm.nih.gov/32949666/

Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson’s Disease Penetrance

San Luciano M, Tanner CM, Meng C, Marras C, Goldman SM, Lang AE, Tolosa E, Schüle B, Langston JW, Brice A, Corvol JC, Goldwurm S, Riboldazzi G, Klein C, Brockman S, Berg D, Brockmann K, Ferreira JJ, Tazir M, Mellick GD, Sue CM, Hasegawa K, Tan EK, Bressman S, Saunders-Pullman R and the Michael J Fox Foundation LRRK2 Cohort Consortium
Mov Disord. 2020 Oct;35(10):1755-1764. doi: 10.1002/mds.28189. Epub 2020 Jul 14.
https://pubmed.ncbi.nlm.nih.gov/32662532/

Expanding Data Collection for the MDSGene Database: X-linked Dystonia-Parkinsonism as Use Case Example

Pauly MG, López MR, Westenberger A, Saranza G, Brüggemann N, Weissbach A, Rosales RL, Diesta CC, Jamora RDG, Reyes CJ, Madoev H , Petkovic S, Ozelius LJ, Klein C, Domingo A
Mov Disord. 2020 Nov;35(11):1933-1938. doi: 10.1002/mds.28289. Epub 2020 Sep 19.
https://pubmed.ncbi.nlm.nih.gov/32949450/

Age at Onset of LRRK2 p.Gly2019Ser Is Related to Environmental and Lifestyle Factors

Lüth T, König IR, Grünewald A, Kasten M, Klein C, Hentati F, Farrer M, Trinh J
Mov Disord. 2020 Oct;35(10):1854-1858. doi: 10.1002/mds.28238. Epub 2020 Sep 2.
https://pubmed.ncbi.nlm.nih.gov/32875616/

Mitochondrial Mechanisms of LRRK2 G2019S Penetrance

Delcambre S, Ghelfi J, Ouzren N, Grandmougin L, Delbrouck C, Seibler P, Wasner K, Aasly JO, Klein C, Trinh J, Pereira SL, Grünewald A
Front Neurol. 2020 Aug 25;11:881. doi: 10.3389/fneur.2020.00881. eCollection 2020.
https://pubmed.ncbi.nlm.nih.gov/31920912/

Scroll to Top